Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort

Key Points

• The central aim is to evaluate how baseline medications affect overall survival in patients treated with immune checkpoint inhibitors for cancer.
• Analysis of patients from the RADIOHEAD cohort treated with immune checkpoint inhibitors.
• Assessment of various baseline medications and their correlation with overall survival.
• Identified significant associations between certain baseline medications and improved overall survival rates.
• Highlighted variability in survival outcomes depending on medication use.